11750 Sorrento Valley Road
About iBio, Inc.
At iBio, we’re pioneering the next generation of biopharmaceuticals using the FastPharming System, our proprietary plant-based recombinant protein manufacturing platform. The speed, safety and scalability inherent in the FastPharming Technology makes it ideal for rapidly advancing promising candidates from concept to clinic, while also enabling “greener” manufacturing. We seek to change the paradigm of drug development by reducing the time, costs, and scale-up issues associated with traditional mammalian cell culture production – thus making plant-based manufacturing the preferred choice for high quality biopharmaceutical development.
Stock Symbol: IBIO
141 articles with iBio, Inc.
iBio Accelerates Transformation to AI-Powered Biotech
BRYAN, Texas and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System
As a leading biotech hub, the second city still ranks far below many other U.S. locations. That is starting to change, however, as new companies move into the heart of the BioMidwest region.
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
Manufactured first batch of drug substance under cGMP conditions Analysis of challenge study data underway
iBio to Participate in the H.C. Wainwright Global Investment Conference
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System,
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System,
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made Molecule
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo
Some might go as far as to consider the pharmaceutical industry as mankind’s best hope for survival. But now, as the world enters the third year of the pandemic, has that perception changed?
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics.
Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?
InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.
Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
iBio, Inc. Enters Into Common Stock Purchase Agreement For Up To $16.0 Million With Lincoln Park Capital
iBio, Inc. Provides Corporate Update At Annual Shareholders Meeting
Another iBio, Inc. Plague Vaccine Patent Issues
iBio, Inc. Expands Product Development Capacity Of cGMP Plant
iBio, Inc. Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development For South African Biotech Company AzarGen Biotechnologies (Pty) Ltd
Implications Of Court Decision In Favor Of iBio, Inc. Against Fraunhofer